Cancer Type: Head and Neck

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

202107012

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

201503060

Phase II Trial of Mitomycin C in Patients with Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

201802162

Los Tres Paso Trial: Step One Neoadjuvant Palbociclib Monotherapy, Step Two Concurrent Chemoradiation Therapy, and Step Three Adjuvant Palbociclib Monotherapy in Patients with p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

202104144

Olaparib in Combination with Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial

202105128

nab-Paclitaxel in Combination with Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma that Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial

201307100

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG 1216)

201405089

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

201712132

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

201802150

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

201804077

An open-label, non-randomized, multi-arm, phase II trial to evaluate the efficacy of pembrolizumab combined with cetuximab in patients with recurrent/ metastatic head and neck squamous cell carcinoma (HNSCC)